canada clinical guidance

Neuropathic pain in adults

A Canadian clinical summary of neuropathic pain in adults, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Pharmacological management of chronic neuropathic pain: revised consensus statement. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CPS neuropathic pain

Source-attributed clinical priorities

  • Identify a plausible lesion or disease of the somatosensory system and document sensory findings rather than diagnosing from descriptors alone.
  • Treat reversible causes and match first-line medication to comorbidity, interactions, renal function and adverse-effect risk.
  • Use function and pain interference as outcomes, titrate one intervention at a time and stop ineffective treatment.
  • Map sensory loss, allodynia and weakness to a plausible neuroanatomic distribution before calling pain neuropathic.
sources for this section:CPS neuropathic pain

Practical assessment and management workflow

1
Establish cause, tempo and distribution and examine strength, reflexes, sensation, gait and skin integrity.
2
Investigate diabetes, alcohol, vitamin deficiency, renal disease, infection, compression or medication causes selectively.
3
Choose one first-line agent around sleep, mood, renal function, falls and interaction risks.
4
Titrate to a predefined trial, measure function and pain interference, and taper if benefit is not meaningful.
sources for this section:CPS neuropathic pain

Safety, red flags and urgent escalation

  • Rapid asymmetric weakness, sphincter change or a new sensory level requires urgent neurologic assessment.
  • Review sedation and driving risk and avoid dangerous combinations with opioids or alcohol.
  • Protect insensate skin and feet from thermal injury, pressure and unnoticed wounds.
sources for this section:CPS neuropathic pain

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CPS neuropathic pain

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CPS neuropathic pain

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Pain SocietyPharmacological management of chronic neuropathic pain: revised consensus statementaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.